ClinicalTrials.gg
CompletedNCT02866825CARDIACUpdated Feb 15, 2017

Studying Complement Inhibition in Complex Cardiac Surgery

A Phase 2 interventional study of IFX-1 and Placebo in Systemic Inflammatory Response Syndrome and C.Surgical Procedure; Cardiac, sponsored by InflaRx GmbH. Completed at 10 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by InflaRx GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Systemic Inflammatory Response Syndrome with a site in Germany — none open to participants now, none under way, none of them phase 3. Systemic Inflammatory Response Syndrome · Germany.

Enrollment
6th of 11
116 · median 116
Started
2016
with 2 others
Phase 2
2 of 19
none open now
Registered
13th of 19
by date
Lead sponsor
2 of 19
InflaRx GmbH

Among the 19 studies in Systemic Inflammatory Response Syndrome with a site in Germany, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2016, is one of 2 in phase 2, and was the 13th registered.

Systemic Inflammatory Response Syndrome

195 studies on the registry are indexed under Systemic Inflammatory Response Syndrome; 24 are open to participants now.

Browse Systemic Inflammatory Response Syndrome studies →

Open to participants now

None of the 19 studies in Systemic Inflammatory Response Syndrome with a site in Germany is open now. The open studies under Systemic Inflammatory Response Syndrome, anywhere →

Who these studies take

Of the 20 Systemic Inflammatory Response Syndrome studies recruiting now, 13 (65%) set no upper age limit and 4 (20%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Systemic Inflammatory Response Syndrome with a site in Germany as a file.
02

Study summary

The trial enrolls patients undergoing a complex cardiac surgery. The primary goal of the trial is to evaluate the pharmacodynamic dose response relationship of the monoclonal antibody IFX-1 in these patients. In addition, this trial further aims to characterize the safety and the pharmacokinetics of IFX-1 as well as to collect first data on its efficacy on clinical surrogate endpoints.

03

Conditions studied

  • Systemic Inflammatory Response Syndrome
  • C.Surgical Procedure; Cardiac

Keywords

  • Inflammation
  • Systemic Inflammatory Response Syndrome
  • Pathologic Processes
  • Organ Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years old
  2. Written
  3. One of the following cardiac surgical procedures is planned with Cardiopulmonary bypass (CPB):

    • Single valve surgery in combination with at least two coronary artery bypass grafts (CABGs)
    • Multiple valve surgery with or without CABG
    • Single or multiple valve surgery in combination with ascending aorta procedure with or without additional CABG
    • Re-surgery of aortic valve, mitral valve, aortic arch or ascending aorta with or without CABG
  4. Cardiac surgery is performed electively

Exclusion criteria

Exclusion Criteria:

  1. Weight > 130 kg
  2. The following cardiac surgical procedures:

    • Cardiac surgical procedure is planned as minimally invasive procedure (e.g., without thoracotomy or with lateral incision, minimal thoracotomy)
    • Cardiac surgery with an expected CPB time less than 100 minutes
  3. Other cardiac and vascular diseases and/or procedures:

    • Prior cardiac surgery within the past 6 months
    • History of heart transplantation or planned heart transplantation
    • Requiring inotropic, vasopressor or mechanical circulatory support
    • Requiring ventilatory support
  4. Other disease or condition that is likely to interfere with the evaluation of the study drug:

    • Active infective endocarditis
    • Stroke or (TIA) within the last 6 months
    • Concomitant disease with a of less than 6 months
    • Cardiopulmonary resuscitation within the last 4 weeks
    • Patients requiring renal replacement therapy
  5. Cerebrovascular disease requiring concomitant carotid endarterectomy
  6. Active infection with or without a temperature greater than 38°C
  7. Presence of systemic inflammatory response syndrome defined as occurrence of at least 2 out of the following 4 criteria:

    • Fever > 38.0°C or hypothermia \< 36.0°C
    • Tachycardia > 90 beats/minute
    • Tachypnea > 20 breaths/minute
    • Leucocytosis > 12 x 109/l or leucopenia \< 4 x 109/l or > 10% immature neutrophils (bands)
  8. Positive test for (HIV), or C
  9. One of the following abnormal laboratory results:

    • \< 5 mmol/l (\< 8.06 g/dl)
    • Total ≥ 2 x upper normal limit (UNL)
    • CRP > 3 x UNL
    • ALAT > 3 x UNL
    • ASAT > 3 x UNL
    • White blood cell count \< 2,500/mm³
    • White blood cell count > 12,000/mm³
  10. Prohibited concomitant medications:

    • Immunomodulatory drugs within past 30 days (e.g., TNF-inhibitors)
    • drugs within past 30 days (e.g., cyclosporine, tacrolimus)
    • High dose (e.g., > 50 mg prednisone/day or equivalent) within past 14 days
    • Any systemic anticancer treatment within the past 3 months
  11. Planned corticosteroid pulse therapy to prevent SIRS
  12. Patients with known to any constituent of the medicinal product (IMP)
  13. General exclusion criteria:

    • Pregnant (in women of an urine pregnancy test has to be performed) or breast-feeding women
    • Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial
    • Participation in any interventional clinical trial within the last three months
    • Prior randomization in this clinical trial (screen failures can be re-screened, if appropriate)
    • Alcohol, drug, or medication abuse
    • Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor
    • No commitment to full aggressive life support (e.g., DNR order)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Active comparator
    IFX-1

    dose escalating single i.v. administration of IFX-1 (verum)

    Biological: IFX-1

  • Placebo comparator
    Placebo

    dose escalating mimicing single i.v. administration of placebo

    Biological: Placebo

Interventions

  • BiologicalIFX-1
  • BiologicalPlacebo
06

What researchers measure

Primary outcomes

  1. Peak level of IL-6

    Time frame: From prior study drug administration until 24h after start of cardiopulmonary bypass (CPB) (CPB)

Secondary outcomes

  1. Plasma concentration of IFX-1 at each timepoint measured

    Time frame: Data will be collected at the following approximate time points: prior study drug administration; 30 min after start of infusion; up to 10 min after cessation of CPB; 3h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15

  2. Maximum observed concentration (Cmax) of IFX-1

    Time frame: Data will be collected at the following approximate time points: prior study drug administration; 30 min after start of infusion; up to 10 min after cessation of CPB; 3h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15

  3. Area under the curve (AUC) of plasma concentration of IFX-1

    Time frame: Data will be collected at the following approximate time points: prior study drug administration; 30 min after start of infusion; up to 10 min after cessation of CPB; 3h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15

  4. Plasma concentration of free, detectable C5a at each timepoint measured

    Time frame: Data will be collected at the following approximate time points: prior study drug administration, prior start of CPB, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15

  5. Serum levels of CH50 at each timepoint measured

    Time frame: Data will be collected at the following approximate time points: prior study drug administration, prior start of CPB, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, 96h, and 168h after start of CPB; Day 15

  6. Serum levels of IL-6 compared to baseline

    Time frame: Data will be collected at the following approximate time points: prior study drug administration, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, and 96h after start of CPB; Day 15

  7. Serum levels of IL-8 compared to baseline

    Time frame: Data will be collected at the following approximate time points: prior study drug administration, up to 10 min after cessation of CPB; 3h, 6h, 12h, 24h, 48h, and 96h after start of CPB; Day 15

  8. Incidence of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs) until Day 29

    Time frame: From screening visit until Day 29

  9. Number of patients with detection of anti-drug-antibodies

    Time frame: Up to Day 15

  10. Number of patients that are successfully extubated 24h after end of surgery

    Time frame: 24h after end of surgery

  11. Number of patients with consecutive invasive ventilation for more than 48h after end of surgery

    Time frame: 48h after end of surgery

  12. Number of patients that are weaned of any vasopressor use 24h after end of surgery

    Time frame: 24h after end of surgery

  13. Number of patients with SIRS 24h, 48h and 96h after start of CPB

    Time frame: 24h, 48h and 96h after start of CPB

07

Study locations

10 sites
  • Study Site
    Aachen, Germany
  • Study Site
    Dortmund, Germany
  • Study Site
    Dresden, Germany
  • Study Site
    Freiburg, Germany
  • Study Site
    Heidelberg, Germany
  • Study Site
    Jena, Germany
  • Study Site
    Kiel, Germany
  • Study Site
    Leipzig, Germany
  • Study Site
    Trier, Germany
  • Study Site
    Tuebingen, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Dec 2016 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2016
First posted
Aug 15, 2016
Start
May 2016
Primary completionActual
Dec 2016
CompletionActual
Jan 2017
Last update
Feb 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02866825
Lead sponsor
InflaRx GmbH
Responsible party
Sponsor
First posted
Aug 15, 2016
Start date
May 2016
Primary completion
Dec 2016
Completion
Jan 2017
Last update
Feb 15, 2017

Study contacts

Torsten Doenst, Prof. Dr.
principal investigator · University Hospital Jena

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilobelimab

Start the discussion